Unfavorable IL-28 Genotype Benefits from the GI-5005 Hep C Vaccine
Share
Follow Us
Hepatitis C Vaccine Elicits Immune Response in Some Patients
By: Diana Mahoney, Internal Medicine News Digital Network
BOSTON – A therapeutic vaccine against the hepatitis C virus was associated with a significantly higher sustained virologic response rate when added to standard-of-care treatment, and the findings justify further development of the vaccine, Dr. Paul Pockros reported at the annual meeting of the American Association for the Study of Liver Diseases.
In the proof-of-concept trial, 133 patients infected with hepatitis C virus (HCV) genotype 1 were randomized to either triple therapy comprising the experimental GI-5005 vaccine, which is designed to elicit a T-cell response specific to HCV, along with pegylated interferon alfa-2b plus ribavirin (P/R), or the standard P/R therapy alone.
Continue reading this entire article:
http://www.ehospitalistnews.com/topics/gastroenterology/single-article-page/hepatitis-c-vaccine-elicits-immune-response-in-some-patients/86315a963a564b69a44cd6c7ee91a7f0.html
